Cannabinoid Derived Pharmaceutical Market Size is valued at USD 12.6 Billion in 2024 and is predicted to reach USD 81.1 Billion by the year 2034 at an 20.8% CAGR during the forecast period for 2025-2034.

Cannabinoids are naturally occurring compounds derived from the Cannabis sativa plant. In recent years, Cannabinoids/medical marijuana have witnessed increased attention due to its growing therapeutic applications in human medicine. Cannabinoid’s active components are potentially effective in treating a variety of conditions, including chronic pain, cancer pain, depression, anxiety disorders, sleep disturbances, and neurological disorders. The recent upsurge in the use and acceptance of CBD can be principally attributed to the onset of cannabis legalization across the United States. Most recently, the passage of the 2018 Farm Bill, which legalized the cultivation of hemp – cannabis with less than 0.3 percent THC by weight.
The demand for cannabinoid extracts and isolates is expected to grow exponentially in the coming years, on account of the anticipated shift in consumer preferences for derivative cannabis product formats, and the applications for cannabinoids in pharmaceutical applications. The market is also driven by growing awareness about the therapeutic benefits paired with healing properties associated with cannabidiol (CBD). Moreover, cannabidiol (CBD) is widely used in several medical applications such as treatment of anxiety and depression, stress relief, diabetes prevention, mitigation of pain, alleviation of cancer symptoms, and acne reduction. The market is expected to show lucrative opportunities over the forecast period owing to the augmented adoption of CBD-based products for treating various medical conditions.
The global Cannabinoid Derived Pharmaceutical market is segmented on the basis of product, application, and region. Based on the products, the market is divided into Cannabinoid Receptor Type 1 (CB1), Cannabinoid Receptor Type 2 (CB2), and Others. On the basis of application type, the market is segmented into Alzheimer’s Disease, Autism, Cancer, Chronic Pain, Epilepsy, Migraine, Multiple Sclerosis, Schizophrenia, and Others. By Formulation segment the market is divided into Oils and Tinctures, Capsules and Tablets, Oral Sprays, Topicals, Others. The Cannabinoid Type category comprises Cannabidiol (CBD), Tetrahydrocannabinol (THC), Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 12.6 Bn |
| Revenue Forecast In 2034 | USD 81.1 Bn |
| Growth Rate CAGR | CAGR of 20.8% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product, By Molecule Type, By Disease Indication, by cannabinoid type, by formulation, By Application, By Source |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; Japan; Brazil; Mexico ; France; Italy; Spain; China; Japan; India; South Korea; South East Asia |
| Competitive Landscape | Cara Therapeutics, Inc., Arena Pharmaceuticals, Cannabics Pharmaceuticals Inc., Echo Pharmaceuticals, GW Pharmaceuticals, InMed Pharmaceuticals, INSYS Therapeutics, Inc., LaraPharm, MGC Pharmaceuticals, Ltd., One World Cannabis, Orpheus Medica, Receptor Life Sciences, RespireRx Pharmaceuticals, Tetra Bio-Pharma, Cardiol Therapeutics, United cannabis Corporation, Zynerba Pharmaceuticals, and List of Other Prominent Players. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Cannabinoid Derived Pharmaceutical Market, by Products, 2025-2034 (Value US$ Mn)
· Natural (Plant-Derived Cannabinoids)
o Epidiolex
o Sativex
o Other Plant-Derived Pipeline Products
· B. Synthetic Cannabinoids
o Marinol
o Syndros
o Cesamet
o Other Synthetic Pipeline Products

Global Cannabinoid Derived Pharmaceutical Market, by Molecule Type, 2025-2034 (Value US$ Mn)
· Cannabinoid Receptor Type 1
· Cannabinoid Receptor Type 2
· Dual / Non-Selective Receptor Modulators
· Others
Global Cannabinoid Derived Pharmaceutical Market, by By Source / Origin
· Plant-Derived Cannabinoids
· Synthetic Cannabinoids
Global Cannabinoid Derived Pharmaceutical Market, by Disease Indication, 2025-2034 (Value US$ Mn)
Global Cannabinoid Derived Pharmaceutical Market, by Formulation
· Oral
· Topical
· Oral Sprays
· Inhalation / Vaporization
· Others
Global Cannabinoid Derived Pharmaceutical Market, by Cannabinoid Type
· CBD-Based Pharmaceuticals
· THC-Based Pharmaceuticals
· Synthetic Cannabinoids
· Minor Cannabinoids & Derivatives
· Cannabinoid Receptor Modulators / Analogues
Global Cannabinoid Derived Pharmaceutical Market, By Distribution Channel
· Hospital Pharmacies
· Retail Pharmacies / Drug Stores
Global Cannabinoid Derived Pharmaceutical Market, By Therapeutic Indication / Application
· Neurological Disorders
· Chronic Pain
· Oncology / Cancer Supportive Care
· Psychiatric & Behavioral Disorders
· Inflammatory & Autoimmune Diseases
Global Cannabinoid Derived Pharmaceutical Market, by Region,
North America Cannabinoid Derived Pharmaceutical Market, by Country,
Europe Cannabinoid Derived Pharmaceutical Market, by Country,
Asia Pacific Cannabinoid Derived Pharmaceutical Market, by Country,
Latin America Cannabinoid Derived Pharmaceutical Market, by Country,
Middle East & Africa Cannabinoid Derived Pharmaceutical Market, by Country,
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.